世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

公的医療予算削減と医薬品企業 2018年:産業調査からの専門家の見解

Constrained Public Healthcare Budgets and the Pharmaceutical Industry - Featuring Expert Panel Views From Industry Survey, 2018

 

出版社 出版年月電子版価格
CBR Pharma Insights
CBRファーマインサイツ
2018年11月US$2,995
シングルユーザライセンス(PDF)

サマリー

米国調査会社CBRファーマインサイツ(CBR Pharma Insights)の調査レポート公的医療予算削減と医薬品企業 2018年:産業調査からの専門家の見解」は、医薬品業界への公的医療予算削減の影響の現状と今後について考察している。医療支出の急増によって、政府は医療費、特にプレミアム医薬品(ブランド医薬品)への支出を制限しようとしている。しかし政府や規制機関はすでに多くの費用抑制のための法規制を導入しており、値付けや払戻しなどの意思決定に関する役割をいまさら変えることは市場に予測できない複雑な変化をもたらすだろう。医薬品企業は製品開発や商業化への道筋における不透明さに直面している。

この調査レポートは、医療費の削減を概観し、世界の医薬品産業への影響に注目している。現在と今後の医療費削減による価格や払戻しに関する業界の専門家や主なオピニオンリーダの意見や見解を収集し、今後の医薬品業界への影響についても記載している。欧州、米国、主要新興地域についてや、今後採用されそうな戦略についても論じている。

Description

 

GBI Research’s latest report: “Constrained Public Healthcare Budgets and the Pharmaceutical Industry - Featuring Expert Panel Views From Industry Survey, 2018” considers the current and future impact of constrained public healthcare budgets on the pharmaceutical industry. Rapidly increased healthcare expenditure is forcing governments to limit healthcare spending, particularly for premium (branded) pharmaceuticals. Hence, governments and regulators have introduced various cost-containment policies, subsequently refining their role in decision making around pricing and reimbursement, thus creating unpredictable and complex changes in marketplace dynamics. Pharma companies face uncertainties en route to product development and commercialization. This report features an overview of constrained healthcare budgets and its effect on the global pharmaceutical industry. GBI Research conducted a targeted industry survey of experts and key opinion leaders to gather insight and opinions on the current and future pricing/reimbursement environment caused by constrained healthcare budgets, and the subsequent impact on the pharmaceutical industry. The survey explored a wide range of strategic topics in the field, including factors contributing to constrained healthcare budgets and the future of healthcare budgets. The report also identifies and discusses the current and future cost-containment policies in European markets, the US and key emerging markets. It explores the current strategies that are being applied by pharma companies in response to pressure stemming from constrained healthcare budgets. The report also discusses the strategies that are most likely to be applied in future.

Scope

  • What are the main factors constraining healthcare budgets?

  • How does constraining healthcare budgets affect the pharmaceutical industry?

  • What is the current pricing and reimbursement landscape like in key mature and emerging pharmaceutical markets?

  • What will the pricing and reimbursement landscape look like in the next five years?

  • What types of cost-containment policies will be implemented/continued in the next five years?

  • What type of value (evaluation criteria) will be important for health technology assessment bodies?

  • What type of managed entry agreements (risk sharing agreement/value-based contracts) will be implemented/continued in the next five years?

  • How are cost-containment policies affecting pharmaceutical companies?

  • How will pressure stemming from constrained healthcare budgets affect the R&D priorities of pharma companies in the next five years?

  • What kind of strategies are pharma companies implementing in response to the pressure stemming from constrained healthcare budgets? How frequently are they being employed? How frequently will they be employed in the next five years?

Reasons To Buy

  • Develop a picture of the current pricing and reimbursement environment brought by constrained healthcare budgets in key mature and emerging markets.

  • Gain insight from industry experts on the future pricing and reimbursement environment (GBI Research survey comprises responses from 46 industry experts and KOLs).

  • Understand how the industry is responding to the challenges and how will it react in the future.



目次

EXECUTIVE SUMMARY

INTRODUCTION

 

2.1 Global Healthcare Expenditure to Reach $9.17 Trillion by 2020

2.2 US Healthcare Expenditure Consistently Higher Than Other Major Markets

2.3 Factors Contributing to Constrained Healthcare Budgets

2.4 GBI Research Industry Survey: Most Important Factors Constraining Healthcare Budgets I

2.5 GBI Research Industry Survey: Therapy Areas Contributing to Constrained Healthcare Budgets I

2.6 How Do Constraining Healthcare Budgets Impact the Pharmaceutical Industry?

 

LANDSCAPE

 

3.1 Pharma in a Changing Environment I

3.2 Current Landscape in Key Mature Markets I

3.3 Current Landscape in Key Emerging Markets I

3.4 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in Europe

3.5 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the US

3.6 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the Asia-Pacific

 

MAIN POLICIES APPLIED IN KEY MARKETS

 

4.1 Main Pricing and Reimbursement Policies Applied in Key Markets II

4.2 Health Technology Assessment Overview

4.3 Heterogeneity in Health Technology Assessment ‘Value’

4.4 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Europe

4.5 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in US

4.6 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Asia-Pacific

4.7 Overview of Managed Entry Agreements (MEA)

4.8 GBI Research Industry Survey: Future of Managed Entry Agreements in Europe

4.9 GBI Research Industry Survey: Future of Managed Entry Agreements in the US

4.10 GBI Research Industry Survey: Future of Managed Entry Agreements in Asia-Pacific

4.11 Pros and Cons of Managed Entry Agreements

 

IMPACT ON PHARMACEUTICAL INDUSTRY

 

5.1 GBI Research Industry Survey: Impact of Constrained Healthcare Budgets on the Pharmaceutical Industry

5.2 Negative impacts of Constrained Healthcare Budgets

5.3 Impact on R&D

5.4 Future R&D priorities

5.5 Perspective of the Industry on Future R&D Priorities

5.6 Positive Impacts of Constrained Healthcare Budgets

5.7 Impact of FDA reforms

 

RESPONSE OF PHARMA COMPANIES

 

6.1 GBI Research Industry Survey: Industry Response

6.2 Strategic Manoeuvres: Mergers and Acquisitions

6.3 Implementation of digital technology

6.4 R&D changes

6.5 Operational changes: Outsourcing

6.6 Payer engagement

6.7 Integrated Care – the Sixth Emerging Business Strategy?

 

CONCLUSION

BIBLIOGRAPHY

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る